Overview Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) Status: Recruiting Trial end date: 2022-08-01 Target enrollment: Participant gender: Summary Radiometabolic Therapy (RMT) with 177Lu PSMA 617 in advanced castration resistant prostate cancer (CRPC): efficacy and toxicity evaluation Phase: Phase 2 Details Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori